Algernon CEO Discusses Ifenprodil Sale to Seyltx and DMT as a Treatment for Stroke and TBI
Christopher Moreau, CEO of Algernon Pharmaceuticals, discusses the company’s sale of Ifenprodil to Seyltx, and their current focus on DMT as a treatment for stroke and traumatic brain injury.